KilgourMD Trial Sets New Bar for Menopausal Hair Loss Treatment

SACRAMENTO, CA – February 19, 2026 – A new hair loss treatment system from dermatologist-founded brand KilgourMD has demonstrated clinically significant hair regrowth and reduced shedding in menopausal women, according to results from a phase II clinical trial announced today. The findings suggest a potent new option for a demographic that has been historically underserved by the hair loss industry, with results appearing in a fraction of the time required by conventional pharmaceutical therapies.

The four-month study evaluated the KilgourMD System, comprising a Prevention and Treatment Serum, in 43 menopausal women diagnosed with androgenetic alopecia, the most common form of hair thinning. The results, which are currently undergoing peer review for publication, could set a new evidence-based benchmark in a market often saturated with cosmetic claims and limited clinical validation for this specific population.

A New Standard for an Underserved Population

For millions of women, menopause brings a host of challenging physiological changes, with hair loss being one of the most distressing. Despite its prevalence, this group has been largely excluded from rigorous hair loss research. Existing mainstream treatments often fall short. Minoxidil, a widely used topical, can take six to twelve months to show results and is ineffective for a substantial portion of menopausal women due to specific enzyme requirements in the scalp. Other pharmaceutical options, such as finasteride, have shown little to no improvement in studies involving this demographic.

The KilgourMD trial directly addresses this gap. By focusing exclusively on menopausal women with clinically significant hair loss, the study provides a clear picture of the system's therapeutic impact. The results were striking: after just 120 days, 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale—a clinical standard used by dermatologists to measure female pattern hair loss. A full one-grade improvement, a substantial visual change, was seen in 26% of participants. This level of progress in just four months is comparable to, and in some cases exceeds, what is typically seen with conventional treatments over a much longer period.

"Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning," said Dr. James Kilgour, the Stanford-trained board-certified dermatologist who founded KilgourMD. "This study validates not only the performance of the KilgourMD System, but also the importance of designing and testing solutions specifically for this population."

Rigorous Science Challenges Industry Norms

In a departure from the cosmetic industry's frequent reliance on self-reported consumer perception, KilgourMD's trial was built on a foundation of objective, scientific measurement. The regrowth outcomes were not just based on what participants thought they saw; they were independently graded by two board-certified dermatologists who were blinded to the treatment timeline. These clinical assessments were further validated with high-resolution digital imaging that documented visible improvements in hair density and scalp coverage over the course of the study.

The quantitative data reinforces the visual findings. Across the entire study group, participants experienced an average 11.1% improvement in their Ludwig score. Beyond regrowth, the system demonstrated a dramatic effect on hair shedding—a primary concern for those experiencing hair loss. Standardized combing and washing assessments revealed a 60% reduction in shedding by the end of the four-month period. This normalization of the hair growth cycle was observed early, with over 95% of participants showing a measurable decrease in hair shedding from their baseline by day 45. While the clinical data provides a robust picture, participant experience was also positive, with over 80% reporting noticeable improvements in their hair's density, health, and overall appearance.

The Science of 'Scalp Aging'

The KilgourMD system is rooted in an emerging scientific concept: "scalp aging." Dr. Kilgour's research led him to the conclusion that, much like skin on the face, the scalp ages, but at an accelerated rate during menopause—potentially up to ten times faster. This process, driven by oxidative stress and inflammation, creates an inhospitable environment for hair follicles, causing them to shrink and eventually become dormant.

The two-serum system is designed to combat this phenomenon at its source. The Prevention Serum acts as a potent antioxidant shield for the scalp, designed to neutralize free radicals and reduce the "inflammaging" that compromises follicular health. The Treatment Serum goes a step further, delivering a concentrated dose of over 15 clinical-strength active ingredients to reactivate dormant follicles.

Central to the formula are proven bio-actives like Redensyl®, a compound shown in studies to target hair follicle stem cells, encouraging them to enter the growth phase. Research on Redensyl®, often combined with other actives like Capixyl® and Procapil® found in the system, has demonstrated superiority to 5% minoxidil in some trials, without the associated side effects. KilgourMD complements these with a proprietary, patent-pending blend of eight botanicals, including turmeric, saw palmetto, and green tea derivatives, which work synergistically to improve microcirculation, inhibit DHT (a hormone linked to hair loss), and further stimulate follicle activity. This multi-pronged approach aims not just to grow hair, but to restore a youthful, healthy scalp environment capable of sustaining long-term growth.

From Personal Mission to Clinical Breakthrough

The driving force behind the brand is not a corporate boardroom but a personal story. Dr. Kilgour, who completed his dermatology residency and a precision medicine fellowship at Stanford University, was inspired to create the company after witnessing his own mother's frustrating and unsuccessful battle with menopause-related hair loss. Even with access to the best available medical options, the treatments were either ineffective or came with side effects that diminished her quality of life.

This personal connection fueled a deep dive into the underlying biology of female hair loss, leading him away from a one-size-fits-all approach and toward the concept of scalp aging. He shifted his own clinical practice to focus on this area and dedicated himself to developing a solution that was both evidence-based and safe. His academic background, which includes publications in top-tier medical journals like JAMA Dermatology and the British Journal of Dermatology, provided the scientific rigor needed to formulate and, now, clinically validate his approach.

This journey from a son's concern to a scientifically validated product represents a new direction in the hair care industry, one that prioritizes deep biological understanding and rigorous clinical testing. As KilgourMD moves forward with the peer-review process for its phase II trial results, the findings already signal a significant step forward in how menopausal hair loss is understood and treated, offering a promising, science-backed solution for millions of women.